Last quarter (Q1 2025), Canaccord Genuity's total revenue was $376.42M, an increase of 29.33% from the same quarter last year. In Q1, Canaccord Genuity's net income was $5.25M. See Canaccord Genuity’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 24	Mar 23	Dec 22	Mar 22	Mar 21
Total Revenue	$ 1.01B	$ 1.28B	$ 1.40B	$ 272.28M	$ 2.05B	$ ―
Cost of Revenue	$ 463.78M	$ ―	$ 1.03B	$ 217.43M	$ ―	$ ―
Gross Profit	$ 1.01B	$ 1.28B	$ 1.40B	$ 54.85M	$ 2.05B	$ ―
Operating Expense	$ 1.01B	$ 1.30B	$ 1.39B	$ 61.13M	$ 1.63B	$ ―
Operating Income	$ -2.52M	$ -21.75M	$ 4.84M	$ -6.28M	$ 416.51M	$ ―
Net Non Operating Interest Income Expense	$ -76.94M	$ ―	$ -54.54M	$ -8.42M	$ -23.60M	$ ―
Other Income Expense	$ -8.90M	$ -9.58M	$ -2.59M	$ 57.00K	$ 14.64M	$ ―
Pretax Income	$ 59.96M	$ 57.07M	$ 74.64M	$ -15.64M	$ 378.27M	$ ―
Tax Provision	$ 21.10M	$ 27.29M	$ 20.31M	$ -4.64M	$ 107.70M	$ ―
Earnings From Equity Interest Net Of Tax	$ -52.00K	$ -70.00K	$ -55.00K	$ ―	$ -192.00K	$ ―
Net Income Common Stockholders	$ 616.00K	$ -13.16M	$ 18.97M	$ 7.80M	$ 246.31M	$ ―
Basic EPS	$ -0.02	$ -0.27	$ -1.16	$ ―	$ 2.60	$ 2.73
Diluted EPS	$ -0.04	$ -0.27	$ -1.16	$ ―	$ 2.25	$ 2.42
Basic Average Shares	$ 279.73M	$ 91.77M	$ 87.38M	$ ―	$ 94.87M	$ 96.66M
Diluted Average Shares	$ 286.83M	$ ―	$ ―	$ ―	$ 109.43M	$ 108.98M
Dividend Per Share	$ 0.27	$ 0.36	$ 0.34	$ ―	$ 0.32	$ 0.25
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ 1.63B	$ ―
Net Income From Continuing And Discontinued Operation	$ 6.32M	$ -13.16M	$ 18.97M	$ 7.80M	$ 246.31M	$ ―
Normalized Income	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ ―	$ ―	$ ―	$ ―	$ 401.87M	$ ―
EBITDA	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―

Currency in USD

Canaccord Genuity Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing